Development of a potent respiratory syncytial virus-specific monoclonal antibody for the prevention of serious lower respiratory tract disease in infants

Respir Med. 2002 Apr:96 Suppl B:S31-5. doi: 10.1053/rmed.2002.1298.
No abstract available

MeSH terms

  • Animals
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal, Humanized
  • Antiviral Agents / administration & dosage*
  • Humans
  • Hybridomas
  • Infant
  • Infant, Newborn
  • Infant, Premature, Diseases / prevention & control*
  • Mice
  • Mice, Inbred BALB C
  • Palivizumab
  • Respiratory Syncytial Virus Infections / prevention & control*
  • Respiratory Syncytial Virus, Human / immunology*
  • Technology, Pharmaceutical
  • Vaccines, Synthetic / administration & dosage*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antiviral Agents
  • Vaccines, Synthetic
  • Palivizumab